Healthy Men Clinical Trial
— DMAUPhase1Official title:
Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men
Verified date | July 2016 |
Source | Los Angeles Biomedical Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The long term objective is to develop a new male hormone Dimethandrolone Undecanoate (DMAU)
as a male hormonal contraceptive.
The study has two parts. The first is a dose escalating study in healthy to assess the safety
and tolerability of single dose oral administration of DMAUin healthy men.(Completed)
The second is to study the safety and tolerability of DMAU after 28 days of repeated daily
dosing of DMAU in healthy men. (Currently Recruiting) In both parts the investigators will
also study the pharmacokinetics of Dimethandrolone (DMA) in the serum after oral
administration of DMAU.
Status | Completed |
Enrollment | 100 |
Est. completion date | May 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: 1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening. 2. 18 to 50 years of age. 3. BMI < 33 calculated as weight in kg/ (height in m2 ) 4. No history of hormonal therapy use in the last three months prior to the first screening visit. 5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, use double-barrier contraception) during the course of the study treatment and recovery phase. 6. Subjects will refrain from donating blood or plasma during the study period. 7. Subjects will be advised to refrain/abstain from alcoholic beverages and grapefruit juice during the study period. 8. Subjects will not use cannabis or any recreational drugs at least 4 weeks before screening and during the study. 9. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form. 10. Does not meet any of the exclusion criteria. Exclusion Criteria: 1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit. 2. Men not living in the catchment's area of the clinic or within a reasonable distance from the study site. 3. Clinically significant abnormal physical and laboratory findings at screening. 4. Elevated PSA (levels = 2.5 ng/mL), according to local laboratory normal values. 5. Abnormal serum chemistry values, according to local laboratory reference ranges that indicate liver or kidney dysfunction or that may be considered clinically significant except for: an upper limit for fasting bilirubin is less than 2 mg/dL, upper limit for cholesterol is less than 220 mg/dL, or upper limit for fasting triglycerides is less than 200 mg/dL. 6. Abnormal semen analyses or abnormal semen concentration as defined by the WHO semen manual. 7. Use of androgens or other body building substances including nutritional supplements within 3 months before first screening visit. 8. Systolic BP > 130 mm Hg and Diastolic blood pressure BP > 80 and mm Hg; ((BP) Blood pressure will be taken 3 times at 5-minute intervals and the mean of all measurements be considered). 9. Clinically significant abnormal EKG and a QTc interval of > 450 msec. 10. PHQ-9 score of 15 or above [for the 28 days study]. 11. History of hypertension, including hypertension controlled with treatment. 12. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis. 13. Benign or malignant liver tumors; active liver disease. 14. History of breast carcinoma. 15. Known history of androgen deficiency due to hypothalamic-pituitary or testicular disease. 16. Known history of cardiac, renal, hepatic or prostatic disease. 17. Positive serology for Hepatitis or HIV at screening visit. 18. A serious systemic disease such as diabetes mellitus or obesity (body weight greater than BMI >33 kg/m2 as above). 19. History of known, untreated sleep apnea. 20. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance. 21. Partner is known to be pregnant. 22. Men desiring fertility within the first 24 weeks of study participation. 23. Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status. |
Country | Name | City | State |
---|---|---|---|
United States | University of Washington | Seattle | Washington |
United States | Los Angeles Biomedical Research Institute | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
Los Angeles Biomedical Research Institute | National Institutes of Health (NIH), University of Washington |
United States,
Attardi BJ, Engbring JA, Gropp D, Hild SA. Development of dimethandrolone 17beta-undecanoate (DMAU) as an oral male hormonal contraceptive: induction of infertility and recovery of fertility in adult male rabbits. J Androl. 2011 Sep-Oct;32(5):530-40. doi: 10.2164/jandrol.110.011817. Epub 2010 Dec 16. — View Citation
Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006 Jun;147(6):3016-26. Epub 2006 Feb 23. — View Citation
Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17ß-undecanoate and 11ß-methyl-19-nortestosterone 17ß-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl. 2011 Mar-Apr;32(2):183-92. doi: 10.2164/jandrol.110.010371. Epub 2010 Aug 26. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men | Number of severe or serious adverse event fdter escalating single doses of Dimethandrolone Undecanoated in a single dose escalating study or after 28 days repeat dosing in healthy men | 1 day | |
Secondary | Single Dose, Dose-Ranging and 28 days Repeat Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men | Serum Dimethandrolone Levels on day 28 | 28 days | |
Secondary | Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men | Serum Dimethandrolone levels | 2 days Food or no food | |
Secondary | Single Dose, Dose-Ranging and 28-Day Repeat-Dose Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Dimethandrolone Undecanoate (DMAU) in Healthy Men | Serum hormone levels (Testosterone (T), FSH and LH and SHBG) and sexual function. | 28 DAYS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02575209 -
Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects
|
N/A | |
Completed |
NCT00900107 -
Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals
|
N/A | |
Completed |
NCT02517775 -
Effects of Cranberry Consumption in Vascular Function in Healthy Individuals
|
N/A | |
Active, not recruiting |
NCT03298373 -
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
|
Phase 1 | |
Completed |
NCT03339167 -
Metabolic Availability of Lysine From Millet in Adult Men
|
N/A | |
Completed |
NCT01710280 -
Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia
|
N/A | |
Completed |
NCT01130948 -
Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects
|
N/A | |
Recruiting |
NCT05523674 -
Effects of Warm-up Intensity and Blood Flow Restriction
|
N/A | |
Not yet recruiting |
NCT05865574 -
A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection
|
Phase 1 | |
Completed |
NCT01293591 -
Garlic Intake And Biomarkers Of Cancer Risk
|
N/A | |
Completed |
NCT01296997 -
Calcium Phosphate and Incretins
|
N/A | |
Completed |
NCT01221558 -
Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men
|
Phase 3 | |
Completed |
NCT00935662 -
A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses
|
Phase 1 | |
Active, not recruiting |
NCT05825781 -
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
|
Phase 1 | |
Completed |
NCT02994602 -
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
|
Phase 1 | |
Completed |
NCT02365987 -
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety
|
N/A | |
Completed |
NCT02093169 -
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
|
Phase 1 | |
Completed |
NCT02072278 -
Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03411005 -
Metabolic Availability of Lysine From Sorghum in Adult Men
|
N/A | |
Recruiting |
NCT02927210 -
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
|
Phase 1 |